MetaCap

Avantor (AVTR) vs Pacific Biosciences of California (PACB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Avantor (AVTR) has outperformed Pacific Biosciences of California (PACB) over the past year, gaining 28.8% versus a loss of 26.6%. Over five years, AVTR leads with a -62.5% price change compared with -93.0% for PACB. Avantor is the larger company by market cap ($10.06 billion vs $508.9 million), about 19.8 times the size, while Pacific Biosciences of California is growing revenue faster (+3.9% vs -3.4%).

Avantor converts more of its revenue into profit, with a net margin of -8.1% versus -341.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVTR+28.82%PACB-26.58%
+55%+0%-55%
Nov 21, 20251 yearNov 20, 2026
AVTR-62.58%PACB-93.84%
+11%-45%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVTR versus PACB key metrics
MetricAVTRPACB
Share price$14.84$1.63
Market cap$10.06B$508.95M
1-day change-1.85%-7.39%
YTD return+29.49%-12.83%
1-year return+28.82%-26.58%
5-year return-62.54%-93.01%
P/E ratio (TTM)29.68—
Forward P/E16.73—
EPS (TTM)$0.50$-0.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.55B$160.00M
Revenue growth (YoY)-3.41%+3.89%
Net income (latest FY)$-530.20M$-546.38M
Gross margin32.65%28.61%
Operating margin-3.76%-346.15%
Net margin-8.09%-341.47%
52-week high$17.45$3.44
52-week low$7.27$1.07
Distance from 52-week high-14.96%-52.62%
Analyst consensusholdbuy
Avg. price target upside+16.91%+68.10%
Average volume8.77M13.23M
Shares outstanding677.62M312.24M
Employees13,500485
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Avantor is about 19.8 times larger than Pacific Biosciences of California by market value ($10.06B vs $508.95M).
  • AVTR has outperformed PACB by 55.4 percentage points over the past year.
  • Avantor is more profitable, keeping -8.1 cents of every revenue dollar as net income versus -341.5 cents for Pacific Biosciences of California.
  • Pacific Biosciences of California grew revenue faster in its latest fiscal year (+3.89% vs -3.41%).

About Avantor

AVTR stock →

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.

Industrials · Biotechnology: Laboratory Analytical Instruments · 13,500 employees

About Pacific Biosciences of California

PACB stock →

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.

Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees

AVTR vs PACB FAQ

Which is bigger, Avantor or Pacific Biosciences of California?

Avantor (AVTR) is larger, with a market capitalization of $10.06B compared with $508.95M for Pacific Biosciences of California (PACB).

Which stock has performed better over the past year, AVTR or PACB?

AVTR returned +28.82% over the past 12 months, compared with -26.58% for PACB (price return, excluding dividends). Past performance does not predict future results.

Are Avantor and Pacific Biosciences of California in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons